NEUROCRINE BIOSCIENCES, INC.

The Basel Area is a leading European hub for life sciences and biotech, attracting major companies like Roche and Novartis. Its appeal lies in a rich ecosystem of research, talent, and infrastructure, making it a prime location for innovation and growth in the sector.

Nxera Pharma received $35m from Neurocrine Biosciences after positive Phase II trial data of NBI-568 in schizophrenia, potentially leading to $2.6bn total and $202m in sales by 2030. The trial met primary endpoint with a 20mg dose significantly reducing symptoms, advancing to Phase III in 2025. Current treatments have significant side effects, driving demand for new medications targeting both positive and negative schizophrenia symptoms.

Neurocrine Biosciences reports positive Phase II results for NBI-1117568, an oral schizophrenia treatment, showing significant symptom reduction and good tolerability.

U.K. plans to enhance clinical trial infrastructure; Neurocrine and Vaderis aim for pivotal studies, while Leo's Timber faces a setback.

Neurocrine Biosciences announced FDA Breakthrough Therapy designation for crinecerfont in congenital adrenal hyperplasia, with a new drug application planned for 2024. The company also updated its R&D portfolio, including advancements in gene therapy and muscarinic compounds, and anticipates Phase 2 data readouts for several programs in 2024.